Recombinant Actinobacillus pleuropneumoniae serotype 3 galactokinase (galK) is an enzymatically active protein produced through genetic engineering. It is derived from the galK gene of A. pleuropneumoniae, a Gram-negative pathogen responsible for porcine pleuropneumonia. This recombinant protein is expressed in heterologous systems such as Escherichia coli, yeast, baculovirus, or mammalian cells, ensuring high purity (≥85% by SDS-PAGE) and functionality . Galactokinase catalyzes the ATP-dependent phosphorylation of galactose to galactose-1-phosphate, a critical step in the Leloir pathway of galactose metabolism.
Recombinant galK is utilized in multiple research contexts:
Enzyme Kinetics: Studies on substrate specificity, catalytic efficiency, and inhibitor screening .
Pathogen Metabolism: Investigating carbon source utilization in A. pleuropneumoniae .
Diagnostic Development: As an antigen for serological assays targeting A. pleuropneumoniae infections .
Structural Biology: Crystallography to resolve galactokinase’s 3D structure for drug design .
Activity confirmed using spectrophotometric assays measuring ATP consumption or galactose-1-phosphate production .
Solubility Issues: Recombinant galK may form inclusion bodies in E. coli, requiring optimized expression conditions .
Functional Redundancy: Other sugar kinases in A. pleuropneumoniae might compensate for galK knockout, complicating phenotypic studies .
Therapeutic Potential: galK is not yet explored as a vaccine candidate, unlike other A. pleuropneumoniae antigens (e.g., LPS components) .
Genetic Conservation: The galK gene is conserved across A. pleuropneumoniae serotypes, suggesting its metabolic indispensability .
Regulatory Networks: galK expression may be modulated by global regulators like ArcA, which represses competing pathways under anaerobic conditions .
Biotechnological Utility: Recombinant galK serves as a tool for synthesizing galactose-1-phosphate in vitro, aiding glycobiology research .
KEGG: apj:APJL_1012